Abstract
INTRODUCTION
Medicare patients currently access amyloid-targeting therapies for Alzheimer’s disease through the class-based National Coverage Determination (NCD) with coverage with evidence development (CED) established in 2022. Evidence addressing the stated CED questions was previously published in a 2024 review; however, the original 2022 NCD remains unchanged.
METHODS
Update the previously published review responding to the CED questions by summarizing recently published donanemab and lecanemab extension data and new safety-related data.
RESULTS
New evidence addresses each of the three CED questions. Extension data show that the benefit of amyloid-targeting therapy continues to accrue with no new safety signals observed. Safety analyses identified baseline risk factors for amyloid-related imaging abnormalities (ARIA). Further, a more gradual donanemab titration regimen decreased risk of ARIA-edema/effusions.
DISCUSSION
With CED questions addressed, reconsideration of the class-based NCD is scientifically justified.
Clinical Trial Registration: NCT04437511, NCT05738486, NCT03887455
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: | August 5, 2026
Neuro-Dementia